Objectives: To provide guidance for the management of mood disorders, based on scientific
evidence supplemented by expert clinical consensus and formulate recommendations to …

Randomized trials have shown that selective serotonin reuptake inhibitors (SSRIs) and
serotonin-norepinephrine reuptake inhibitors (SNRIs) have better safety profiles than …

The prevalence and public health burden of chronic heart failure (CHF) in Europe is steadily
increasing mainly caused by the ageing population and prolonged survival of patients with …

Background Pharmacological augmentation is a recommended strategy for patients with
treatment-resistant depression. A range of guidelines provide advice on treatment selection …

Body dysmorphic disorder (BDD) is a relatively common and often disabling disorder with
high morbidity and mortality. Both psychotropic medication and cognitive behavioral therapy …

The essential contribution of the antidepressant-sensitive serotonin (5-HT) transporter SERT
(which is encoded by the SLC6A4 gene) to platelet 5-HT stores suggests an important role …

Context: Major depressive disorder (MDD) can be challenging to diagnose in patients with
congestive heart failure, who often suffer from fatigue, insomnia, weight changes, and other …

Heart failure (HF) is a burgeoning chronic health condition affecting more than 20 million
people worldwide. Patients with HF have a significant (17.1%) 30-day readmission rate …

OBJECTIVE: This article reviews recent studies relating to the impact of depression and its
treatment on the health-related quality of life (HRQOL) of patients with coronary artery …

Background Patients with heart failure often experience depressive symptoms that affect
health-related quality of life, morbidity, and mortality. Researchers have not described the …